Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
OSE-127/Lusvertikimab
FR104/VEL-101
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
Back to agenda
Date
07/06/2022
Hours
6:30 p.m. CET / 12:30 a.m. ET
Place
Conference call
Conference call for analysts to comment the updated data presented at the 2022 ASCO meeting
Four Poster Presentations at ASCO 2022 Annual Meeting
Conference call for analysts to comment the updated data presented at the 2022 ASCO meeting
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient Reported Outcomes Versus Chemotherapy
Positive Interim Results in Phase 2 Trial of Tedopi® in Pancreatic Cancer in Maintenance Strategy Post-FOLFIRINOX (GERCOR)
Link to the webcast